Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TWST 
Twist Bioscience Corp (TWST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: TWST (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $39.43
1 Year Target Price $39.43
| 6 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.08% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.70B USD | Price to earnings Ratio - | 1Y Target Price 39.43 |
Price to earnings Ratio - | 1Y Target Price 39.43 | ||
Volume (30-day avg) 12 | Beta 2.39 | 52 Weeks Range 24.07 - 55.33 | Updated Date 10/19/2025 |
52 Weeks Range 24.07 - 55.33 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -23.52% | Operating Margin (TTM) -31.36% |
Management Effectiveness
Return on Assets (TTM) -13.88% | Return on Equity (TTM) -17.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1679225179 | Price to Sales(TTM) 4.69 |
Enterprise Value 1679225179 | Price to Sales(TTM) 4.69 | ||
Enterprise Value to Revenue 4.64 | Enterprise Value to EBITDA -35.26 | Shares Outstanding 60360925 | Shares Floating 59140427 |
Shares Outstanding 60360925 | Shares Floating 59140427 | ||
Percent Insiders 1.77 | Percent Institutions 118.2 |
Upturn AI SWOT
Twist Bioscience Corp
Company Overview
History and Background
Twist Bioscience Corp. was founded in 2013 and is headquartered in South San Francisco, California. It is a synthetic biology company known for its DNA synthesis platform and silicon-based manufacturing process. The company has evolved from providing synthetic DNA to offering biopharma solutions like antibody discovery.
Core Business Areas
- Synthetic Biology: Manufacturing synthetic DNA for various applications, including drug discovery, agriculture, and industrial biotechnology.
- Biopharma: Providing antibody discovery and optimization services leveraging its DNA synthesis platform. Focuses on developing therapeutic antibodies.
- Genomics and Sequencing: Offers products and services for next-generation sequencing (NGS) sample preparation and target enrichment.
Leadership and Structure
Emily Leproust is the CEO and co-founder. The company has a typical corporate structure with a board of directors and various executive leadership positions overseeing different departments like R&D, operations, and sales.
Top Products and Market Share
Key Offerings
- Synthetic Genes: Custom-made DNA sequences for research, drug development, and industrial applications. Competitors include IDT (Integrated DNA Technologies) and GenScript. Market share information is difficult to obtain precisely, but Twist is considered a significant player in the synthetic DNA market. Revenue contributions aren't publicly broken down by product, but synthetic genes are a core offering.
- Antibody Discovery: Services for discovering and optimizing antibodies for therapeutic purposes. Competitors include companies offering antibody discovery services like Charles River Laboratories and WuXi Biologics. Revenue is growing quickly in this segment.
- NGS Target Enrichment: Kits and reagents for preparing samples for next-generation sequencing. Competitors include Illumina and Agilent. This segment helps in improving DNA detection and analysis.
Market Dynamics
Industry Overview
The synthetic biology market is rapidly growing, driven by advancements in DNA sequencing and synthesis technologies and the increasing demand for personalized medicine and sustainable manufacturing. The antibody discovery market is also experiencing substantial growth, fueled by the development of new therapeutics.
Positioning
Twist Bioscience is positioned as a disruptive innovator in the synthetic biology space due to its silicon-based DNA synthesis platform, offering high throughput and cost-effectiveness. Their competitive advantage lies in their ability to produce large quantities of high-quality DNA at a competitive price.
Total Addressable Market (TAM)
The total addressable market (TAM) for synthetic biology is estimated to reach billions of dollars, with projections varying depending on the source and scope. Twist is targeting key segments within this TAM including pharmaceuticals, diagnostics and data storage. The biopharma segment is seeing increased interest from investors, positioning Twist to potentially take a substantial portion of the TAM as it grows.
Upturn SWOT Analysis
Strengths
- Proprietary silicon-based DNA synthesis platform
- High throughput and scalable manufacturing process
- Strong IP portfolio
- Growing presence in the biopharma sector
- Established relationships with leading research institutions and companies
Weaknesses
- Relatively high operating expenses
- Reliance on a few key customers
- Negative profitability
- Requires substantial capital investment for expansion
- Susceptible to fluctuations in demand
Opportunities
- Expanding into new application areas for synthetic DNA
- Increasing adoption of its biopharma services
- Forming strategic partnerships and collaborations
- Capitalizing on the growing demand for personalized medicine
- Expanding into new geographic markets
Threats
- Competition from established players in the synthetic biology market
- Price pressure from commoditization of synthetic DNA
- Regulatory hurdles for synthetic biology products
- Economic downturn affecting research funding
- Potential for technological disruptions
Competitors and Market Share
Key Competitors
- IDT
- GHDX
Competitive Landscape
Twist Bioscience competes with established players like IDT in the synthetic DNA market. Twist's silicon-based platform provides a cost advantage, while competitors may have a larger established customer base.
Major Acquisitions
Abveris
- Year: 2021
- Acquisition Price (USD millions): 190
- Strategic Rationale: Strengthened Twist's antibody discovery capabilities and expanded its presence in the biopharma market.
Growth Trajectory and Initiatives
Historical Growth: Twist Bioscience has experienced strong revenue growth in recent years, driven by increasing demand for its synthetic DNA and biopharma services.
Future Projections: Analysts project continued revenue growth for Twist Bioscience, driven by expansion into new markets and applications. Profitability remains a key focus.
Recent Initiatives: Recent initiatives include expanding its biopharma capabilities, investing in new manufacturing facilities, and forming strategic partnerships.
Summary
Twist Bioscience is a disruptive company with a unique DNA synthesis platform and shows potential in synthetic biology and biopharma. It is achieving strong revenue growth, but it is still unprofitable and has high operating expenses. Its biopharma sector is seeing investor interest, but Twist needs to manage cash flow effectively and navigate competition to achieve sustainable success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Earnings Call Transcripts
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change, so it is crucial to do further research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Twist Bioscience Corp
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-10-31 | Co-Founder, Board Chair & CEO Dr. Emily Marine Leproust Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 923 | Website https://www.twistbioscience.com |
Full time employees 923 | Website https://www.twistbioscience.com | ||
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.